BRPI0922619A2 - compostos de plasmalogen, composições farmacêuticas contendo os mesmos e métodos para tratar doenças do envelhecimento - Google Patents
compostos de plasmalogen, composições farmacêuticas contendo os mesmos e métodos para tratar doenças do envelhecimentoInfo
- Publication number
- BRPI0922619A2 BRPI0922619A2 BRPI0922619A BRPI0922619A BRPI0922619A2 BR PI0922619 A2 BRPI0922619 A2 BR PI0922619A2 BR PI0922619 A BRPI0922619 A BR PI0922619A BR PI0922619 A BRPI0922619 A BR PI0922619A BR PI0922619 A2 BRPI0922619 A2 BR PI0922619A2
- Authority
- BR
- Brazil
- Prior art keywords
- plasmalogen
- compounds
- methods
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
- 230000032683 aging Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13969508P | 2008-12-22 | 2008-12-22 | |
| PCT/CA2009/001853 WO2010071988A1 (en) | 2008-12-22 | 2009-12-18 | Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0922619A2 true BRPI0922619A2 (pt) | 2016-09-13 |
| BRPI0922619A8 BRPI0922619A8 (pt) | 2023-01-10 |
Family
ID=42286823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0922619A BRPI0922619A8 (pt) | 2008-12-22 | 2009-12-18 | Compostos de plasmalogen, composições farmacêuticas contendo os mesmos e métodos para tratar doenças do envelhecimento |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9334235B2 (pt) |
| EP (1) | EP2382201B1 (pt) |
| JP (2) | JP5740312B2 (pt) |
| KR (1) | KR101810988B1 (pt) |
| CN (2) | CN102369193B (pt) |
| AR (2) | AR074854A1 (pt) |
| AU (1) | AU2009329784B2 (pt) |
| BR (1) | BRPI0922619A8 (pt) |
| CA (1) | CA2746831C (pt) |
| IL (1) | IL213409A0 (pt) |
| MX (1) | MX350291B (pt) |
| MY (1) | MY169797A (pt) |
| RU (1) | RU2546108C2 (pt) |
| SG (1) | SG172340A1 (pt) |
| TW (1) | TWI475989B (pt) |
| UY (1) | UY32359A (pt) |
| WO (1) | WO2010071988A1 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010100060A2 (en) * | 2009-03-04 | 2010-09-10 | Nestec S.A. | Method for increasing endogenous plasmalogen levels in mammals |
| SG10201405975VA (en) | 2009-10-01 | 2014-11-27 | Phenomenome Discoveries Inc | Serum-based biomarkers of pancreatic cancer and uses thereof for diseasedetection and diagnosis |
| JP5997887B2 (ja) * | 2011-09-05 | 2016-09-28 | 学校法人帝京大学 | 経口投与剤 |
| JP5934483B2 (ja) * | 2011-09-05 | 2016-06-15 | 学校法人帝京大学 | リン脂質結合型dha増加剤 |
| WO2015064960A1 (ko) | 2013-10-29 | 2015-05-07 | 울산대학교 산학협력단 | 플라스마로젠 전구체, 플라스마로젠 또는 플라스마로젠 유사체를 유효성분으로 함유하는 간질환 예방 또는 치료용 약학조성물 |
| WO2016041013A1 (en) * | 2014-09-16 | 2016-03-24 | Baker Idi Heart And Diabetes Institute Holdings Limited | Glycerolipids and uses therefor |
| CN108276438B (zh) * | 2018-02-02 | 2020-05-22 | 中国海洋大学 | 一种epa缩醛磷脂的制备方法及其应用 |
| CN112166116B (zh) | 2018-04-27 | 2024-04-12 | 株式会社流变机能食品研究所 | 新型缩醛磷脂衍生物 |
| WO2020009173A1 (ja) * | 2018-07-06 | 2020-01-09 | 丸大食品株式会社 | プラズマローゲン含有組成物 |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| CN112321446A (zh) * | 2020-11-25 | 2021-02-05 | 华南理工大学 | 一种酰胺衍生物的合成方法 |
| CN113150270A (zh) * | 2021-03-19 | 2021-07-23 | 广东丁沃生医疗器械有限公司 | 一种磷脂聚合物及其制备方法与应用 |
| JP7704407B2 (ja) * | 2021-08-04 | 2025-07-08 | 株式会社 レオロジー機能食品研究所 | がん治療用組成物 |
| JP7629164B2 (ja) * | 2021-08-23 | 2025-02-13 | 株式会社 レオロジー機能食品研究所 | 新規プラズマローゲン誘導体 |
| KR20240113765A (ko) | 2021-11-22 | 2024-07-23 | 가부시키가이샤 레오로지 키노쇼쿠힝겐큐죠 | 화합물, 이의 라세미체, 이들의 염, 조성물, 항염증제, 인지증 치료제 및 레트 증후군 치료제 |
| WO2024111529A1 (ja) * | 2022-11-21 | 2024-05-30 | 株式会社 レオロジー機能食品研究所 | 脳プラズマローゲン増加剤、脳プラズマローゲン増加用経口組成物及び化合物の使用 |
| WO2025057845A1 (ja) * | 2023-09-11 | 2025-03-20 | 株式会社 レオロジー機能食品研究所 | 抗老化剤、抗老化用経口組成物及び化合物の使用 |
| CN119876292B (zh) * | 2025-03-27 | 2025-06-03 | 浙江省白马湖实验室有限公司 | 一种酰胺类缩醛磷脂化合物的制备方法及应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4827011A (en) * | 1984-12-10 | 1989-05-02 | American Cyanamid Company | Antihypertensive phosphate derivatives |
| FR2736265B1 (fr) | 1995-07-07 | 1997-09-26 | Forgeot Marcel | Nouvelles compositions a base de phosphoglycero ethers et leur utilisation dans le traitement des maladies neuro-degeneratives |
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| JP2004026803A (ja) | 2002-03-29 | 2004-01-29 | Nof Corp | 神経細胞死予防剤 |
| US20080020472A1 (en) | 2005-11-22 | 2008-01-24 | Frantz Biomarkers, Llc | Method for detecting an inflammatory disease or cancer |
| KR20080104350A (ko) | 2006-02-28 | 2008-12-02 | 페노미넘 디스커버리스 인코포레이티드 | 치매 및 다른 신경 장애의 진단을 위한 방법 |
| US20080021000A1 (en) | 2006-07-19 | 2008-01-24 | Su Chen | Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species |
| JP2008125365A (ja) * | 2006-11-16 | 2008-06-05 | Kagoshima Univ | 高純度プラスマローゲン調製法 |
| JPWO2008093709A1 (ja) * | 2007-01-30 | 2010-05-20 | 株式会社プロジェクト・エム | アミロイド蛋白質の凝集抑制および分解促進によりアミロイドーシスと関連する疾患を予防または治療するための組成物 |
| EP2620147B1 (en) | 2007-02-08 | 2020-06-03 | Med-Life Discoveries LP | Compounds for lowering cholesterol |
| JP5220842B2 (ja) | 2007-04-13 | 2013-06-26 | フェノメノーム ディスカバリーズ インク | プラスマロゲン欠乏症が媒介する加齢に伴う疾患の診断及びリスク評価のための方法 |
-
2009
- 2009-12-16 TW TW098143152A patent/TWI475989B/zh active
- 2009-12-18 WO PCT/CA2009/001853 patent/WO2010071988A1/en not_active Ceased
- 2009-12-18 BR BRPI0922619A patent/BRPI0922619A8/pt not_active Application Discontinuation
- 2009-12-18 MX MX2011006795A patent/MX350291B/es active IP Right Grant
- 2009-12-18 EP EP09833973.2A patent/EP2382201B1/en active Active
- 2009-12-18 KR KR1020117015617A patent/KR101810988B1/ko active Active
- 2009-12-18 MY MYPI2011002904A patent/MY169797A/en unknown
- 2009-12-18 CN CN200980157183.5A patent/CN102369193B/zh active Active
- 2009-12-18 US US13/141,035 patent/US9334235B2/en active Active
- 2009-12-18 RU RU2011124579/04A patent/RU2546108C2/ru active
- 2009-12-18 CA CA2746831A patent/CA2746831C/en active Active
- 2009-12-18 CN CN201610221350.XA patent/CN105859680A/zh active Pending
- 2009-12-18 SG SG2011045994A patent/SG172340A1/en unknown
- 2009-12-18 JP JP2011541046A patent/JP5740312B2/ja active Active
- 2009-12-18 AU AU2009329784A patent/AU2009329784B2/en active Active
- 2009-12-22 AR ARP090105048A patent/AR074854A1/es active IP Right Grant
- 2009-12-22 UY UY0001032359A patent/UY32359A/es not_active Application Discontinuation
-
2011
- 2011-06-06 IL IL213409A patent/IL213409A0/en active IP Right Grant
-
2015
- 2015-03-16 JP JP2015052549A patent/JP2015145388A/ja active Pending
-
2019
- 2019-05-16 AR ARP190101307A patent/AR117572A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX350291B (es) | 2017-09-04 |
| US9334235B2 (en) | 2016-05-10 |
| TW201034662A (en) | 2010-10-01 |
| CN105859680A (zh) | 2016-08-17 |
| UY32359A (es) | 2010-05-31 |
| IL213409A0 (en) | 2011-07-31 |
| JP2012512816A (ja) | 2012-06-07 |
| AU2009329784B2 (en) | 2016-08-25 |
| CA2746831A1 (en) | 2010-07-01 |
| AR074854A1 (es) | 2011-02-16 |
| US20120035250A1 (en) | 2012-02-09 |
| MY169797A (en) | 2019-05-15 |
| CN102369193A (zh) | 2012-03-07 |
| WO2010071988A1 (en) | 2010-07-01 |
| MX2011006795A (es) | 2011-09-26 |
| EP2382201B1 (en) | 2022-08-24 |
| EP2382201A4 (en) | 2015-11-18 |
| US20130116312A2 (en) | 2013-05-09 |
| SG172340A1 (en) | 2011-07-28 |
| WO2010071988A8 (en) | 2011-07-21 |
| KR20110104002A (ko) | 2011-09-21 |
| CN102369193B (zh) | 2016-05-04 |
| TWI475989B (zh) | 2015-03-11 |
| JP2015145388A (ja) | 2015-08-13 |
| RU2546108C2 (ru) | 2015-04-10 |
| CA2746831C (en) | 2013-11-26 |
| BRPI0922619A8 (pt) | 2023-01-10 |
| KR101810988B1 (ko) | 2017-12-20 |
| JP5740312B2 (ja) | 2015-06-24 |
| RU2011124579A (ru) | 2013-01-27 |
| EP2382201A1 (en) | 2011-11-02 |
| AR117572A2 (es) | 2021-08-18 |
| AU2009329784A1 (en) | 2011-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0922619A2 (pt) | compostos de plasmalogen, composições farmacêuticas contendo os mesmos e métodos para tratar doenças do envelhecimento | |
| BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
| BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
| BR112014003681A2 (pt) | composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições | |
| BRPI0810082A2 (pt) | 3-imidazolil-indóis para o tratamento de doenças proliferativas | |
| BR112013026341A2 (pt) | composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia | |
| BR112014029674A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença, utilização de um composto, conjunto para o tratamento de uma condição mediada pela quinase pim e invenção | |
| BR112012026570A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado | |
| BR112014008126A2 (pt) | composto, método para o tratamento, composição farmacêutica, utilização de um composto e invenção | |
| PT2367561E (pt) | Composições e métodos para o tratamento da doença celíaca | |
| BRPI0813725A2 (pt) | Métodos e composições para tratamento de doenças | |
| BRPI0916684A2 (pt) | Compostos de piperazina, composição, e, processo para combater vegetação indesejada | |
| BRPI1005153A2 (pt) | composto, composição farmacêutica, uso de um composto, metodo para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação | |
| BRPI0908026A2 (pt) | Métodos para o tratamento de doenças do intestino | |
| BRPI0911685A2 (pt) | composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit | |
| BRPI0919238A2 (pt) | métodos e composições para o tratamento de câncer | |
| PT2632452T (pt) | Compostos e composições para o tratamento do cancro | |
| BRPI0909164A2 (pt) | método e composições para o tratamento de câncer | |
| BR112015006512A2 (pt) | composição para tratar tecidos biológicos danificados | |
| BR112014009889A2 (pt) | compostos dissubstituídos, compostos e composição farmacêutica | |
| BRPI0908334A2 (pt) | kit, composição, produto ou medicamento para tratar comprometimento cognitivo | |
| BRPI0911580A2 (pt) | composições para o tratamento de uma condição artrítica | |
| BR112014001015A2 (pt) | agente de cura para composições de cura por umidade | |
| BRPI0923909A2 (pt) | Método para tratar uma ou mais hastes de cabelo | |
| BRPI0917562A2 (pt) | composições farmacêuticas e métodos para estabilizar as mesmas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: MED-LIFE DISCOVERIES LP (CA) |
|
| B25G | Requested change of headquarter approved |
Owner name: MED-LIFE DISCOVERIES LP (CA) |